Introduction
Methods
Systematic literature search
AGREE II evaluation
Scope and purpose | |
1 | The overall objective(s) of the guideline is (are) specifically described |
2 | The health question(s) covered by the guideline is (are) specifically described |
3 | The population (e.g., patients, public) to whom the guideline is meant to apply is specifically described |
Stakeholder involvement | |
4 | The guideline development group includes individuals from all relevant professional groups |
5 | The views and preferences of the target population (e.g., patients, public) have been sought |
6 | The target users of the guideline are clearly defined |
Rigor of development | |
7 | Systematic methods were used to search for evidence |
8 | The criteria for selecting the evidence are clearly described |
9 | The strengths and limitations of the body of evidence are clearly described |
10 | The methods for formulating the recommendations are clearly described |
11 | The health benefits, side effects and risks have been considered in formulating the recommendations |
12 | There is an explicit link between the recommendations and the supporting evidence |
13 | The guideline has been externally reviewed by experts before its publication |
14 | A procedure for updating the guideline is provided |
Clarity of presentation | |
15 | The recommendations are specific and unambiguous |
16 | The different options for management of the condition or health issue are clearly presented |
17 | Key recommendations are easily identifiable |
Applicability | |
18 | The guideline describes facilitators and barriers to its application |
19 | The guideline provides advice and/or tools on how the recommendations can be put into practice |
20 | The potential resource implications of applying the recommendations have been considered |
21 | The guideline presents monitoring and/or auditing criteria |
Editorial independence | |
22 | The views of the funding body have not influenced the content of the guideline |
23 | Competing interests of guideline development group members have been recorded and addressed |
Interrater reliability assessment
Results
Selected CPGs
First author | Development group | Abbreviation | Region of origin/focus | Funding | Intended users | Evidence base | Guideline content |
---|---|---|---|---|---|---|---|
Becker [3] | German Society of Dermatology | DDG | Germany | Project Deal | Multidisciplinary | Expert consensus, literature review | Diagnosis and treatment of MCC |
Craighead [9] | Alberta Health Services | AHS | Canada | AHS | Multidisciplinary | Expert consensus, literature review | Diagnosis and treatment of MCC |
Doval [12] | Spanish Academy of Dermatology and Venereology | AEDV | Spain | AEDV | Multidisciplinary | Expert consensus, literature review | Diagnosis and treatment of MCC |
Gauci [13] | European Dermatology Forum, the European Association of Dermato-Oncology, and the European Organization of Research and Treatment of Cancer | EDF/EADO/EORTC | Europe | – | Multidisciplinary | Expert consensus, literature review | Diagnosis and treatment of MCC |
Naseri [22] | Danish MCC Expert Group | DEG | Denmark | – | Multidisciplinary | Expert consensus, systematic literature review | Diagnosis and treatment of MCC |
Schmults [26] | National Comprehensive Cancer Network | NCCN | United States | NCCN Foundation | Multidisciplinary | Expert consensus, systematic literature review | Diagnosis and treatment of MCC |
Silk [27] | Society for Immunotherapy of Cancer | SITC | United States | SITC | Multidisciplinary | Expert consensus, literature review | Immunotherapy for treatment of nonmelanoma skin cancer |
Spada [28] | Italian Association of Medical Oncology | AIOM | Italy | Merck, Pfizer | Multidisciplinary | Expert consensus, literature review | Diagnosis and treatment of MCC |
Quality designations
Guideline | Domain 1: Scope and purpose (%) | Domain 2: Stakeholder involvement (%) | Domain 3: Rigor of development (%) | Domain 4: Clarity of presentation (%) | Domain 5: Applicability (%) | Domain 6: Editorial independence (%) | Mean overall score | Quality appraisal |
---|---|---|---|---|---|---|---|---|
DDG | 27.78 | 31.94 | 22.92 | 93.06 | 78.13 | 97.92 | 58.62 | Moderate |
AHS | 97.22 | 61.11 | 64.06 | 97.22 | 36.46 | 93.75 | 74.97 | High |
AEDV | 88.89 | 50.00 | 84.90 | 95.83 | 38.54 | 87.50 | 74.28 | Moderate |
EDF/EADO/EORTC | 81.94 | 63.89 | 75.00 | 86.11 | 82.29 | 89.58 | 79.80 | High |
DEG | 45.83 | 48.61 | 48.96 | 86.11 | 45.83 | 89.58 | 60.82 | Low |
NCCN | 48.61 | 43.06 | 63.02 | 97.22 | 59.38 | 83.33 | 65.77 | Moderate |
SITC | 66.67 | 45.83 | 55.21 | 94.44 | 65.63 | 87.50 | 69.21 | Moderate |
AIOM | 69.44 | 52.78 | 57.81 | 70.83 | 46.88 | 81.25 | 63.17 | Moderate |
Mean ± SD | 65.80 ± 23.71 | 49.65 ± 10.12 | 58.98 ± 18.47 | 90.10 ± 8.98 | 56.64 ± 17.55 | 88.80 ± 5.33 | 65.80 ± 23.71 |
Interrater reliability
AGREE II domain | ICC | 95% CI |
---|---|---|
Domain 1: Scope and purpose | 0.96 | [0.77, 1.00] |
Domain 2: Stakeholder involvement | 0.99 | [0.94, 1.00] |
Domain 3: Rigor of development | 0.98 | [0.94, 1.00] |
Domain 4: Clarity of presentation | 0.74 | [0.53, 0.99] |
Domain 5: Applicability | 0.94 | [0.70, 1.00] |
Domain 6: Editorial independence | 0.83 | [0.11, 1.00] |